Search

Your search keyword '"MESH: Eye Neoplasms"' showing total 3 results
Start Over Descriptor "MESH: Eye Neoplasms" Topic business.industry
3 results on '"MESH: Eye Neoplasms"'

1. Ocular adnexal lymphoma and Helicobacter pylori gastric infection

Author

Claire Mathiot, J. Girodet, Nicole Brousse, Jean-Luc Beretti, Frédéric Mal, Corine Plancher, Bernard Asselain, Pierre Validire, Agnès Ferroni, Livia Lumbroso-Le Rouic, Kheira Beldjord, Patricia Validire, Patricia de Cremoux, Rémi Dendale, Anne Vincent-Salomon, E Macintyre, Marc Lecuit, Didier Decaudin, Olivier Hermine, Institut Curie [Paris], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Paris Descartes - Paris 5 (UPD5), Institut Mutualiste de Montsouris (IMM), Microorganismes et Barrières de l'Hôte (Equipe avenir), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur [Paris], Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Curie, and Equipe avenir Microorganismes et Barrières de l'Hôte

Subjects
Male, Pathology, MESH: Eye Neoplasms, Gastroenterology, Cohort Studies, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, MESH: Lymphoma, B-Cell, Marginal Zone, Stomach cancer, MESH: Cohort Studies, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, MESH: Aged, MESH: Middle Aged, Hematology, biology, Stomach, digestive, oral, and skin physiology, Middle Aged, 3. Good health, medicine.anatomical_structure, Gastritis, 030220 oncology & carcinogenesis, Medicine, Female, MESH: Gastritis, medicine.symptom, Adult, medicine.medical_specialty, Helicobacter Infections, 03 medical and health sciences, Ocular Adnexal Lymphoma, Internal medicine, medicine, Humans, Aged, Gastric Infection, MESH: Humans, Helicobacter pylori, business.industry, Eye Neoplasms, MESH: Helicobacter Infections, MESH: Adult, Lymphoma, B-Cell, Marginal Zone, biology.organism_classification, medicine.disease, digestive system diseases, MESH: Male, Lymphoma, 030221 ophthalmology & optometry, MESH: Helicobacter pylori, business, MESH: Female
Abstract

There is a causal association between Helicobacter pylori (Hp) gastric infection and the development of gastric MALT lymphoma. In contrast, the link between Hp gastric infection and the development of extragastric lymphoma has not been thoroughly investigated. We, therefore, studied the prevalence of gastric Hp infection at initial diagnosis of ophthalmologic and nonophthalmologic extragastric lymphoma patients. Three cohorts of patients were studied: a first one of 83 patients with OAL, a second one of 101 patients with extraophthalmologic extragastric lymphoma, and a third one of 156 control individuals (control) without malignant lymphoma. Gastric Hp infection was investigated by histopathological analysis and Hp-specific PCR assay on gastric biopsy tissue samples. We found gastric Hp infection in 37 OAL patients (45%), in 25 extraophthalmologic extragastric lymphoma cases (25%), and in 18 controls individuals (12%) (P < 0.0001 OAL/C and P < 0.01 OAL/extra-OAL cases). Gastritis was found in 51% and 9% of Hp-positive and Hp-negative lymphoma patients, respectively (P < 10−4). Gastric Hp infection only correlated with MALT/LPL lymphoma (P = 0.03). There is a significant association between gastric Hp infection and MALT/LPL OAL. This suggests a novel mechanism of indirect infection-associated lymphomagenesis whereby chronic local antigen stimulation would lead to the emergence of ectopic B-cell lymphoma. © 2010 Wiley-Liss, Inc. Am. J. Hematol.

Published
2010

2. Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma

Author

Christian Berthou, Jean-Christophe Ianotto, Catherine Marianowski-Cochard, Adrian Tempescul, Olivier Pradier, Michel, Geneviève, Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, Service Hématologie, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], Laboratoire de Traitement de l'Information Medicale (LaTIM), Université européenne de Bretagne - European University of Brittany (UEB)-Télécom Bretagne-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Mines-Télécom [Paris] (IMT), Department of Ophthalmology, University Hospital Brest, and Université européenne de Bretagne - European University of Brittany (UEB)

Subjects
Oncology, medicine.medical_specialty, MESH: Combined Modality Therapy, [SDV.IMM] Life Sciences [q-bio]/Immunology, medicine.medical_treatment, MESH: Eye Neoplasms, 03 medical and health sciences, 0302 clinical medicine, MESH: Aged, 80 and over, Internal medicine, Medicine, Combined Modality Therapy, ComputingMilieux_MISCELLANEOUS, MESH: Aged, Chemotherapy, Hematology, MESH: Humans, business.industry, General Medicine, medicine.disease, MESH: Injections, Intravenous, 3. Good health, Radiation therapy, MESH: Antineoplastic Combined Chemotherapy Protocols, Local radiotherapy, 030220 oncology & carcinogenesis, MESH: Radiotherapy, Conformal, 030221 ophthalmology & optometry, Combined therapy, [SDV.IMM]Life Sciences [q-bio]/Immunology, Intraocular lymphoma, MESH: Platinum Compounds, business, MESH: Lymphoma
Abstract

International audience

Published
2011

3. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire

Author

Soussain, Carole, Hoang-Xuan, Khê, Taillandier, Luc, Fourme, Emmanuelle, Choquet, Sylvain, Witz, Francis, Casasnovas, Olivier, Dupriez, Brigitte, Souleau, Bertrand, Taksin, Anne-Laure, Gisselbrecht, Christian, Jaccard, Arnaud, Omuro, Antonio, Sanson, Marc, Janvier, Maud, Kolb, Brigitte, Zini, Jean-Marc, Leblond, Véronique, Renseigné, Non, Biologie des Interactions Neurones / Glie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de neurologie 1 [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Réseau d'Etude des Gliomes, REG, Service de Neuro-Oncologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service d'hématologie-oncologie adultes, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie biologique [CHU Limoges], CHU Limoges, UPMC - Département de neurologie 2 - Mazarin, Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Service de Neurologie [CHU Pitié-Salpêtrière], IFR70-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Pitié-Salpêtrière [APHP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, Oncology, Cancer Research, MESH: Combined Modality Therapy, MESH: Busulfan, medicine.medical_treatment, Salvage therapy, Hematopoietic stem cell transplantation, MESH: Eye Neoplasms, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, MESH: Cytarabine, Prospective Studies, Etoposide, MESH: Etoposide, MESH: Aged, MESH: Middle Aged, Brain Neoplasms, MESH: Thiotepa, Cytarabine, Hematopoietic Stem Cell Transplantation, Middle Aged, Combined Modality Therapy, 3. Good health, MESH: Salvage Therapy, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, 030220 oncology & carcinogenesis, MESH: Brain Neoplasms, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Lymphoma, Large B-Cell, Diffuse, Intraocular lymphoma, Stem cell, MESH: Neoplasm Recurrence, Local, medicine.drug, Adult, medicine.medical_specialty, MESH: Survival Rate, 03 medical and health sciences, Multicenter trial, Internal medicine, medicine, Humans, Busulfan, Cyclophosphamide, MESH: Hematopoietic Stem Cell Transplantation, Aged, Salvage Therapy, Chemotherapy, MESH: Humans, business.industry, Eye Neoplasms, MESH: Cyclophosphamide, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, Lymphoma, MESH: Lymphoma, Large B-Cell, Diffuse, Methotrexate, Neoplasm Recurrence, Local, business, human activities, MESH: Female, Thiotepa, 030217 neurology & neurosurgery
Abstract

Purpose The prognosis of relapsing primary CNS lymphoma (PCNSL) is poor. We report the results of a prospective multicenter trial of intensive chemotherapy followed by autologous hematopoietic stem-cell rescue (IC + HCR) in immunocompetent adult patients with PCNSL or intraocular lymphoma (IOL) after failure of high-dose methotrexate-based treatment. Patients and Methods Salvage treatment consisted of two cycles of high-dose cytarabine and etoposide (CYVE). Intensive chemotherapy combined thiotepa, busulfan, and cyclophosphamide. Forty-three patients (median age, 52 years; range, 23 to 65 years) were included, with relapse (n = 22), refractory disease (n = 17), or a partial response to first-line treatment (n = 4). The response to CYVE was not assessable in three cases because of treatment-related death. Twenty patients (47%) were chemosensitive to CYVE: 15 of them proceeded to IC + HCR. IC + HCR was also administered to 12 patients who did not respond to CYVE. All but one of the 27 patients who underwent IC + HCR entered complete remission. Results With a median follow-up of 36 months, the median overall survival was 18.3 months in the overall population, and 58.6 months among patients who completed IC + HCR. The respective median progression-free survival (PFS) times after IC + HCR were 11.6 and 41.1 months. The 2-year overall survival probability was 45% in the whole population and 69% among the 27 patients who received IC + HCR. The 2-year PFS probability was 43% among all the patients and 58% in the IC + HCR subpopulation. Conclusion IC + HCR is an effective treatment for refractory and recurrent PCNSL.

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results